GetTopicDetailResponse(id=52e6105693c, topicName=KRAS基因, introduction=KRAS基因, content=null, image=null, comments=2, allHits=1861, url=https://h5.medsci.cn/topic?id=10569, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=4309, tagList=[TagDto(tagId=4309, tagName=KRAS基因)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2218149, encodeId=4c1c22181494b, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小細(xì)胞肺癌#</a> <a href='/topic/show?id=52e6105693c' target=_blank style='color:#2F92EE;'>#KRAS基因#</a>, objectTitle=真實(shí)世界，KRAS基因G12C突變肺癌的治療路徑？生存時(shí)間多長(zhǎng)？, objectType=article, longId=837176, objectId=702b83e1769d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240627/1719487025893_5579292.jpg, objectUrl=/article/show_article.do?id=702b83e1769d, replyNumber=0, likeNumber=85, createdTime=2024-08-02, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=702b83e1769d, moduleTitle=真實(shí)世界，KRAS基因G12C突變肺癌的治療路徑？生存時(shí)間多長(zhǎng)？, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=702b83e1769d)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2205199, encodeId=71b82205199f0, content=<a href='/topic/show?id=493ae869206' target=_blank style='color:#2F92EE;'>#結(jié)直腸癌#</a> <a href='/topic/show?id=2eaa9048456' target=_blank style='color:#2F92EE;'>#西妥昔單抗#</a> <a href='/topic/show?id=52e6105693c' target=_blank style='color:#2F92EE;'>#KRAS基因#</a>, objectTitle=KRAS基因突變的腸癌，雙靶向治療的策略獲美國(guó)NCCN指南推薦！, objectType=article, longId=825370, objectId=cb4d8253e090, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240517/1715928072081_5579292.jpg, objectUrl=/article/show_article.do?id=cb4d8253e090, replyNumber=0, likeNumber=99, createdTime=2024-05-17, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=cb4d8253e090, moduleTitle=KRAS基因突變的腸癌，雙靶向治療的策略獲美國(guó)NCCN指南推薦！, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=cb4d8253e090)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2161113, encodeId=3815216111374, content=<a href='/topic/show?id=02d4106e783b' target=_blank style='color:#2F92EE;'>#Divarasib#</a>（GDC-6036）是一種篩選出來(lái)的小分子靶向藥，對(duì)于<a href='/topic/show?id=52e6105693c' target=_blank style='color:#2F92EE;'>#KRAS基因#</a>G12C突變翻譯成的蛋白具有高效選擇性抑制能力，可以不可逆地將突變的KRAS鎖定在非活性狀態(tài)，關(guān)閉致癌信號(hào)。體外試驗(yàn)證實(shí)Divarasib的效力是<a href='/topic/show?id=8482106e793b' target=_blank style='color:#2F92EE;'>#sotorasib#</a> （<a href='/topic/show?id=b64e106e80cc' target=_blank style='color:#2F92EE;'>#索托拉西布#</a>，AMG510）和 <a href='/topic/show?id=28ff106e8105' target=_blank style='color:#2F92EE;'>#adagrasib#</a> （<a href='/topic/show?id=adc410636149' target=_blank style='color:#2F92EE;'>#阿達(dá)格拉西布#</a>）的 5 至 20 倍，選擇性高達(dá) 50 倍。, objectTitle=體外抑制活性增強(qiáng)5到20倍的KRAS新藥Divarasib，肺癌腸癌、多種實(shí)體腫瘤都有效！, objectType=article, longId=792690, objectId=121de926907d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/ccd0b61f0a3894a4bf51f2d065f58b9849794aa5.jpg, objectUrl=/article/show_article.do?id=121de926907d, replyNumber=0, likeNumber=0, createdTime=2023-10-06, rootId=0, userName=俠膽醫(yī)心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=121de926907d, moduleTitle=體外抑制活性增強(qiáng)5到20倍的KRAS新藥Divarasib，肺癌腸癌、多種實(shí)體腫瘤都有效！, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=121de926907d)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=1613685, encodeId=6ed71613685da, content=<a href='/topic/show?id=52e6105693c' target=_blank style='color:#2F92EE;'>#KRAS基因#</a>, objectTitle=LANCET ONCOL :Selumetinib與多西他賽聯(lián)合治療KRAS基因突變晚期NSCLC療效佳, objectType=article, longId=12811, objectId=3d99128118f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d99128118f, replyNumber=0, likeNumber=91, createdTime=2012-12-12, rootId=0, userName=ms7514935887898259, userId=3cc819405474, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d99128118f, moduleTitle=LANCET ONCOL :Selumetinib與多西他賽聯(lián)合治療KRAS基因突變晚期NSCLC療效佳, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=3d99128118f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
